Aravind Palraj: What Is the Best Targeted Therapy Approach After Cancer Remission?

Aravind Palraj, D.M Rheumatology resident в Madras Medical College, shared on X:

“Inflammatory arthritis + history of cancer – can targeted therapy still be used?

Key EULAR points:

• Previous cancer in remission does not automatically mean biologics must be delayed
• Assess individual recurrence risk and use shared decision-making
• After prior solid cancer, a TNF inhibitor may be preferred when targeted therapy is needed
• After prior lymphoma, B-cell – depleting therapy may be preferred
• JAK inhibitors and abatacept should be used cautiously when suitable alternatives are lacking If cancer is not in remission, treatment decisions should be multidisciplinary with oncology input.

Other posts featuring Aravind Palraj on OncoDaily.